SCHEMBL6935650

SCHEMBL6935650

O=P(Br)(OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.63
CETP P11597 3/20 0.47
IDO1 P14902 1/20 0.44
SRC P12931 1/20 0.44
PDPK1 O15530 1/20 0.43
MTOR P42345 1/20 0.43
AGXT P21549 1/20 0.43
ALPG P10696 1/20 0.43
PTK2B Q14289 1/20 0.43
ALDH1A1 P00352 2/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
FOLH1 Q04609 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206609 0.81 TSHR (0.68) TSHRCETPIDO1SRCPDPK1
SCHEMBL3705675 0.79 TSHR (0.65) TSHRCETPIDO1SRCPDPK1
SCHEMBL3367144 0.78 TSHR (0.64) TSHRCETPSRCPDPK1MTOR
SCHEMBL5032692 0.78 TSHR (0.59) TSHRCETPIDO1SRCPDPK1
SCHEMBL389180 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1
SCHEMBL8533600 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1
SCHEMBL12831300 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1
SCHEMBL79996 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1
SCHEMBL14263644 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1
SCHEMBL8361083 0.77 TSHR (0.63) TSHRCETPIDO1SRCPDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720050-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2026-04-08 EP claimed
EP-4074719-B1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC SYNTHETIC PHARMACEUTICAL CO LTD (CN) 2025-12-03 EP claimed
US-12173020-B2 New-type oxazolidinone compounds and preparation method therefor HC Synthetic Pharmaceutical Co., Ltd. (CN) 2024-12-24 US claimed
WO-2024249672-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2024-12-05 WO claimed
CN-117567455-A Novel oxazolidinone compound and synthetic method and application thereof 华创合成制药股份有限公司 2024-02-20 CN claimed
US-20230046407-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC Synthetic Pharmaceutical Co., Ltd. (CN) 2023-02-16 US claimed
EP-4074719-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC Synthetic Pharmaceutical Co., Ltd. (CN) 2022-10-19 EP claimed
EP-0998518-B1 PROCESS FOR THE PREPARATION OF POLYETHER PHOSPHATES AMERSHAM HEALTH AS (NO) 2003-12-10 EP claimed
EP-4720050-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2026-04-08 EP disclosed
EP-4074719-B1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC SYNTHETIC PHARMACEUTICAL CO LTD (CN) 2025-12-03 EP disclosed
US-12173020-B2 New-type oxazolidinone compounds and preparation method therefor HC Synthetic Pharmaceutical Co., Ltd. (CN) 2024-12-24 US disclosed
WO-2024249672-A1 PROCESS OF PREPARING HIV CAPSID INHIBITOR GILEAD SCIENCES, INC. (US) 2024-12-05 WO disclosed
CN-117567455-A Novel oxazolidinone compound and synthetic method and application thereof 华创合成制药股份有限公司 2024-02-20 CN disclosed
US-20230046407-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC Synthetic Pharmaceutical Co., Ltd. (CN) 2023-02-16 US disclosed
EP-4074719-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR HC Synthetic Pharmaceutical Co., Ltd. (CN) 2022-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046407-A1 NEW-TYPE OXAZOLIDINONE COMPOUNDS AND PREPARATION METHOD THEREFOR CYP4F11, OXA1L, WEE2 TSHR 3107/4885CETP 2341/4885IDO1 4429/4885
US-12173020-B2 New-type oxazolidinone compounds and preparation method therefor CYP4F11, OXA1L, WEE2 TSHR 3107/4885CETP 2341/4885IDO1 4429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.